Manager × security

J. Goldman & Co LP REGN holdings history

Who else holds this security? →

REGENERON PHARMACEUTICALS · CUSIP 75886F107 · CIK 1412741

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, J. Goldman & Co LP reported 6.94K REGN (shares), valued at $4.32M, or 0.15% of its reported non-derivative portfolio. Filed 2026-08-14.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
0.15%
Shares
6.94K
6,936
Reported value
$4.32M
USD

Shares decreased 57.36%; reported value decreased 65.59%, and weight changed -0.43 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20260.15%6,936SEC filing ↗Filed Aug 14, 2026
Q1 20260.58%16,268SEC filing ↗Filed May 15, 2026
Q4 20250.19%6,352SEC filing ↗Filed Feb 17, 2026
Q3 20250.45%21,266SEC filing ↗Filed Nov 14, 2025
Q2 20250.56%33,846SEC filing ↗Filed Aug 14, 2025
Q1 20250.33%14,886SEC filing ↗Filed May 15, 2025
Q4 20240.32%12,588SEC filing ↗Filed Feb 14, 2025
Q3 20240.41%8,894SEC filing ↗Filed Nov 14, 2024
Q2 20240.22%5,686SEC filing ↗Filed Aug 14, 2024
Q1 20240.29%6,598SEC filing ↗Filed May 15, 2024
Q4 20232.24%45,603SEC filing ↗Filed Feb 14, 2024
Q3 20231.88%45,620SEC filing ↗Filed Nov 14, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 20231.88%45,620$37.54MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Nov 14, 2023
Q4 20232.24%45,603$40.05MShares decreased 0.04%; reported value increased 6.68%, and weight changed +0.36 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2024
Q1 20240.29%6,598$6.35MShares decreased 85.53%; reported value decreased 84.14%, and weight changed -1.95 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2024
Q2 20240.22%5,686$5.98MShares decreased 13.82%; reported value decreased 5.89%, and weight changed -0.07 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2024
Q3 20240.41%8,894$9.35MShares increased 56.42%; reported value increased 56.45%, and weight changed +0.19 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2024
Q4 20240.32%12,588$8.97MShares increased 41.53%; reported value decreased 4.10%, and weight changed -0.09 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2025
Q1 20250.33%14,886$9.44MShares increased 18.26%; reported value increased 5.29%, and weight changed +0.01 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2025
Q2 20250.56%33,846$17.77MShares increased 127.37%; reported value increased 88.21%, and weight changed +0.23 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2025
Q3 20250.45%21,266$11.96MShares decreased 37.17%; reported value decreased 32.71%, and weight changed -0.11 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2025
Q4 20250.19%6,352$4.90MShares decreased 70.13%; reported value decreased 59.00%, and weight changed -0.26 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 17, 2026
Q1 20260.58%16,268$12.57MShares increased 156.11%; reported value increased 156.36%, and weight changed +0.39 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2026
Q2 20260.15%6,936$4.32MShares decreased 57.36%; reported value decreased 65.59%, and weight changed -0.43 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2026
J. Goldman & Co LP · REGENERON PHARMACEUTICALS

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1412741","quarter":"2026Q2","cusip":"75886F107"}

get_institutional_manager_history
{"cik":"1412741","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.